Diosmin, 600 mg 30 pcs.

Diosmin

Indications

• Varicose veins of the lower extremities (elimination of symptoms);
• Chronic lymphovenous insufficiency of the lower extremities (elimination of symptoms);
• Acute hemorrhoids (in complex therapy to relieve symptoms);
• Microcirculation disorders (for example, with idiopathic edema).

Pharmacological effect

Pharmacotherapeutic group: angioprotective agent.

ATX code: C05CA03

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics
Diosmin belongs to the group of bioflavonoids, has a phlebotonic effect (reduces the distensibility of veins, increases the tone of the veins (dose-dependent effect), reduces venous stagnation), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases the resistance of capillaries (dose-dependent effect), reduces them permeability), reduces the adhesion of leukocytes to the venous wall and their migration into paravenous tissues, improves the diffusion of oxygen and
perfusion in skin tissue, has an anti-inflammatory effect. Strengthens the vasoconstrictor effect of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.

Pharmacokinetics
Diosmin is quickly absorbed from the gastrointestinal tract. Detected in blood plasma 2 hours after administration. Bioavailability of the drug after oral administration is approximately 40-57.9%.
Part of the drug is metabolized by bacteria of the cecum with the formation of hippuric and benzoic acids.
The maximum concentration in blood plasma is achieved 5 hours after administration. The drug accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities, to a lesser extent – in
kidneys, liver and lungs and other tissues.
The volume of distribution of the drug is 62.1 l. The maximum selective accumulation of diosmin and/or its metabolites in the wall of venous vessels is observed 9 hours after administration and persists for 96 hours.
Diosmin is rapidly metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid. Diosmin metabolites are excreted primarily by the kidneys in the form of conjugates with glucuronic acid. 79% of taken diosmin is excreted by the kidneys, 11% by the intestines, and 2.4% by the bile. Enterohepatic circulation of the drug is noted. After taking radiolabeled diosmin
approximately 86% of the drug is excreted by the kidneys and intestines within 48 hours.

Special instructions

Treatment of acute hemorrhoids is carried out in combination with other drugs. If there is no rapid clinical effect, it is recommended to consult a proctologist, if necessary, conduct an additional examination and adjust the therapy.

In case of venous circulation disorders (varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities), the maximum treatment effect is ensured by a combination of therapy with lifestyle changes: it is advisable to avoid prolonged stay in an upright position and reduce excess body weight. In some cases, wearing special stockings (compression stockings) helps improve blood circulation.

There is insufficient experience with the use of diosmin in children under 18 years of age.

If there is no improvement or if the symptoms of the disease worsen, consult a doctor!

Do not exceed the maximum duration and recommended doses of the drug without consulting your doctor!

Impact on the ability to drive vehicles and machinery
The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Diosmin

Composition

Active ingredient:
diosmin in terms of anhydrous substance – 600,000 mg.

Excipients:
gelatin – 7,800 mg,
sodium carboxymethyl starch (type A) – 19,400 mg,
magnesium stearate – 9,700 mg,
microcrystalline cellulose – up to 970,000 mg.

Shell composition:
opadry II 85F240012 Pink – 30,000 mg:
polyvinyl alcohol – 12,000 mg,
Macrogol-3350 – 7.314 mg,
red iron oxide dye – 0.120 mg,
iron dye yellow oxide – 0.066 mg,
talc – 4.440 mg,
titanium dioxide – 6,060 mg

Pregnancy

Experience with the drug in pregnant women is limited. No adverse reactions have been reported when using diosmin in pregnant women in clinical practice. Experimental studies have not revealed the teratogenic effects of diosmin on pregnancy, embryofetal and postnatal development. However, for safety reasons, the use of the drug in the first trimester of pregnancy is contraindicated. If it is necessary to use the drug during the second and third trimesters of pregnancy, it is recommended to first consult a doctor.
During breastfeeding, taking the drug is not recommended, because There is no data on the penetration of diosmin into breast milk.

Contraindications

• Hypersensitivity to the components of the drug;
• Children under 18 years of age (experience of use is limited);
• Pregnancy (first trimester) and breastfeeding period (experience of use is limited).

Side Effects

The frequency of side effects is determined in accordance with the WHO classification of adverse drug reactions by frequency of occurrence: very often – more than 1/10, often – more than 1/100 and less than 1/10, infrequently – more than 1/1000 and less than 1/100, rarely – more than 1/10000 and less than 1/1000, very rarely – less than 1/10000, including isolated cases; unknown frequency (determine frequency
According to the available data, the incidence of adverse reactions is impossible).

From the gastrointestinal tract:
often – nausea, vomiting, diarrhea (diarrhea), dyspeptic disorders, heartburn, constipation;
infrequently – colitis.

From the central nervous system:
rarely – headache, dizziness.

From the skin and subcutaneous fat:
rarely – skin rashes, skin itching;

Allergic reactions:
rarely – urticaria, unknown frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema (Quincke’s edema).

General disorders:
rarely – malaise.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Clinically significant interactions of diosmin with other drugs have not been described.

Overdose

Cases of overdose have not been described. Given the wide therapeutic range of diosmin, the risk of toxicity in case of overdose appears to be negligible.
The specific antidote is unknown.
In case of overdose of the drug, seek medical help immediately!

Storage conditions

In a place protected from light at a temperature not exceeding 25 °C.
Keep out of reach of children

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Ozon, Russia